Is it appropriate to switch a patient who is currently using the transdermal estradiol patch (Climara) and not achieving relief to the vaginal estradiol soft‑gel capsule (Veozah)?

Veozah Is Not Appropriate for This Patient – Climara Failure Requires Optimization or Alternative Estrogen Therapy

Veozah (fezolinetant) is a non-hormonal neurokinin-3 receptor antagonist approved only for vasomotor symptoms (hot flashes); it does not treat genitourinary symptoms, does not provide bone protection, and cannot replace systemic estrogen therapy in a patient currently using Climara (transdermal estradiol). 1

---

Why Veozah Cannot Replace Climara

• Veozah addresses only vasomotor symptoms (hot flashes, night sweats) by blocking neurokinin-3 receptors in the hypothalamic thermoregulatory center; it provides no estrogen replacement and therefore offers no benefit for vaginal dryness, dyspareunia, bone loss, or cardiovascular protection. 1

• Climara delivers systemic estradiol, which treats vasomotor symptoms, prevents accelerated bone loss (reducing fractures by 22–27%), improves genitourinary symptoms by 60–80%, and maintains cardiovascular health when initiated within 10 years of menopause. 1, 2

• Switching from systemic estrogen to Veozah eliminates all estrogen-dependent benefits except partial hot-flash control, leaving the patient vulnerable to osteoporosis, genitourinary atrophy, and loss of metabolic protection. 1

---

Correct Management When Climara "Is Not Working"

Step 1: Define What "Not Working" Means

• If vasomotor symptoms persist despite Climara, verify the patch dose (standard is 50 µg twice weekly), confirm proper application technique (clean, dry, intact skin on lower abdomen, upper buttocks, or back; avoid areas with friction or excessive hair), and check for patch detachment or inadequate adhesion. 3

• If genitourinary symptoms (vaginal dryness, dyspareunia) persist, add low-dose vaginal estrogen (e.g., 10 µg estradiol vaginal tablet twice weekly or vaginal estradiol ring) because systemic estrogen alone may not fully restore vaginal epithelium in some women. 1, 2

• If the patient has breakthrough bleeding or mood symptoms, assess progestogen regimen (if uterus intact) and consider switching from synthetic progestin to micronized progesterone 200 mg nightly for 12–14 days per cycle, which has superior tolerability. 1

Step 2: Optimize Transdermal Estrogen Delivery

• Increase the Climara dose to 0.075 mg or 0.1 mg patch if symptoms remain uncontrolled on the standard 0.05 mg dose; dose titration every 4–8 weeks based on symptom response (not hormone levels) is the evidence-based approach. 1

• Switch to a different transdermal estradiol formulation (gel, spray, or alternative patch brand) if adhesion problems or skin irritation limit Climara use; transdermal delivery remains first-line because it avoids the 28–39% stroke risk increase and 2–4-fold VTE risk elevation seen with oral estrogen. 1, 3

• Consider oral 17β-estradiol 1–2 mg daily only if all transdermal options fail or are contraindicated; oral estradiol is second-line due to hepatic first-pass metabolism but remains safer than conjugated equine estrogen. 3

Step 3: Rule Out Contraindications That Have Developed

• Verify the patient has not developed new absolute contraindications (breast cancer, VTE, stroke, coronary artery disease, active liver disease, antiphospholipid syndrome) that would mandate estrogen discontinuation regardless of formulation. 1

• Assess cardiovascular risk factors (blood pressure, smoking status, diabetes, hyperlipidemia) because uncontrolled hypertension or smoking in women >35 years amplifies stroke and clot risk with any estrogen therapy. 1

---

When Veozah Might Be Appropriate (But Not in This Case)

• Veozah is indicated only when estrogen therapy is contraindicated (e.g., personal history of breast cancer, prior VTE, stroke, or coronary disease) and the patient has isolated moderate-to-severe vasomotor symptoms without need for bone or genitourinary protection. 1

• Veozah does not require progestogen because it is non-hormonal, making it suitable for women with an intact uterus who cannot tolerate progestins—but this advantage is irrelevant if the patient needs systemic estrogen for multiple indications. 1

• Veozah has no long-term safety data beyond 52 weeks, whereas transdermal estradiol has decades of evidence supporting use until at least age 60 or 10 years post-menopause in women without contraindications. 1

---

Critical Pitfalls to Avoid

• Never discontinue systemic estrogen in a woman <60 years or <10 years post-menopause who lacks contraindications, because the risk-benefit profile strongly favors continued estrogen therapy for symptom control, bone protection, and cardiovascular health. 1

• Do not assume Veozah is "safer" than estrogen simply because it is non-hormonal; Veozah carries hepatotoxicity warnings (requires baseline and periodic liver function monitoring) and does not address the full spectrum of menopausal symptoms. 1

• Avoid switching therapies without first optimizing the current regimen—most "estrogen failures" result from inadequate dosing, poor adherence, or lack of adjunctive vaginal estrogen rather than true treatment resistance. 1, 2

---

Evidence-Based Algorithm for This Patient

1. Confirm the Climara dose and application technique; if suboptimal, correct these factors before changing therapy. 3

2. If vasomotor symptoms persist on optimized transdermal estrogen, increase the patch dose to 0.075–0.1 mg or switch to estradiol gel 1.5–3 mg daily. 1

3. If genitourinary symptoms persist, add vaginal estradiol 10 µg tablet twice weekly or vaginal estradiol ring (does not require additional progestogen). 1, 2

4. If the patient has an intact uterus, ensure she is receiving micronized progesterone 200 mg nightly for 12–14 days per cycle (or continuously) to prevent endometrial hyperplasia. 1

5. Reassess at 4–8 weeks; if symptoms remain uncontrolled despite maximal transdermal estrogen and adjunctive vaginal estrogen, consider oral 17β-estradiol 2 mg daily as second-line. 3

6. Reserve Veozah only for patients with absolute contraindications to estrogen who have isolated vasomotor symptoms and do not require bone or genitourinary protection. 1